Shilpa Medicare gets nod to manufacture, market Lenvatinib capsules

31 Jan 2020 Evaluate

Shilpa Medicare has received approval from Central Drugs Standard Control Organisation (CDSCO) -New Delhi to manufacture and market Lenvatinib capsules 4mg and 10mg in India. It is the first company to obtain Generic approval for Lenvatinib Capsules 4mg and 10mg in India.

Lenvatinib capsules 4mg and 10mg is a generic equivalent of reference product, Lenvima, used in the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer and for the first line treatment of patients with unresectable hepatocellular carcinoma. According to IQVIA MAT Q2 2019 data, the Indian market for Lenvatinib capsules 4mg and 10mg is approximately $0.32 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.


Shilpa Medicare Share Price

535.95 -9.55 (-1.75%)
29-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.